复力捷改善碘乙酸钠引起大鼠骨关节炎及其早期安全性研究OA

Objective:To explore the therapeutic effects of Fulijie on sodium iodoacetate-induced osteoarthritis in rats and investigate its early safety profile.Methods:A total of 57 SD rats were randomly divided into the blank control group,model group,high,medium,and low-dose Fulijie groups(400,200,100 mg·kg-1),and a celecoxib group(80 mg·kg-1).After the rats' knee joints were injec-ted with sodium iodoacetate for one day,rats were treated with continuous oral administration for 21 days.Body weight changes were recorded,and the threshold of foot withdrawal was measured.The pathological damage of the knee in each group was observed by H&E staining,and the Mankin score for histopathological evaluation was applied.Organ coefficients were measured in the high-dose group,and serum levels of organ toxicity indicators were assessed.The levels of total superoxide dismutase(SOD)and malondialdehyde(MDA)in the knee tissue were measured,and the expression of tumor necrosis factor-α(TNF-α)in the knee tissue was detected by ELISA.Results:Compared to the model group,all Fulijie-treated groups(high,medium,and low doses)showed improvement in the osteoarthri-tis damage in rats,with the high-dose group demonstrating significantly better efficacy,even superior to approved drug celecoxib.The high-dose group notably reversed the decrease in SOD activity and the increase in MDA levels caused by sodium iodoacetate-induced osteo-arthritis model,while reducing the expression of TNF-α in knee tissue.Toxicity tests in the high-dose group,including organ coefficients and toxicity markers,revealed no significant changes,indicating no obvious toxicity.Conclusion:Fulijie effectively ameliorates sodium iodoacetate-induced osteoarthritis in rats,likely through anti-inflammatory and antioxidative mechanisms.Additionally,Fulijie shows no obvious toxic and side effects,indicating a favorable safety profile.